Safety and Efficacy of Broad Band Light In Motion Treatment
Characterization of Safety and Efficacy of Broad Band Light In Motion Treatment for Pigmented Skin Lesions on Chest, Arms and Back
1 other identifier
interventional
7
1 country
1
Brief Summary
Evaluate safety and efficacy of Broad Band Light (BBL) motion technique treatment for pigmentation, skin tone and texture
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Apr 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 12, 2019
CompletedFirst Submitted
Initial submission to the registry
May 29, 2019
CompletedFirst Posted
Study publicly available on registry
May 31, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 30, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
September 29, 2020
CompletedOctober 20, 2020
October 1, 2020
1.4 years
May 29, 2019
October 19, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Photographs
Evaluation of Photographs using Physician's Global Assessment Scale (0-4) where 0 is no change and 4 is very significant improvement
6 weeks
Study Arms (1)
Broad Band Light
EXPERIMENTALBroad Band Light (BBL) motion treatment
Interventions
Eligibility Criteria
You may qualify if:
- Healthy male or female, 18 years or older
- Fitzpatrick skin type I-V
- Has visible signs of moderate to severe skin pigmentation
- Subject must agree to not make any changes in their skin regimen for the duration of the study, including the follow-up period
- Subject must be able to read, understand and sign Informed Consent Form
- Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation, educational or marketing purposes
- Willing to have very limited sun exposure and use an approved sunscreen of SPF 50 or higher on the treatment area every day for the duration of the study, including the follow-up period
- Must be willing to adhere to the treatment and follow-up schedule and post-treatment care instructions
- Agree to not use any other procedure(s) in the treatment area during the study, such as laser- or light-based treatment, non-light based device treatment such as radiofrequency or ultrasound, injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler, chemical peel, or surgical procedure
- Post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study, and no plans to become pregnant or to father a child for the duration of the study
You may not qualify if:
- Participation in a clinical trial of another device or drug within 6 months prior to enrollment or during the study.
- Any type of prior cosmetic treatment to the target area within 3 months of study participation, such as laser or light-based procedures or surgery.
- Prior injection of botulinum toxin, collagen, hyaluronic acid filler or other dermal filler in the target area within 1 week of study participation.
- History of malignant tumors in the target area.
- Skin abnormalities in the target area, e.g., cuts, scrapes, wounds, scars, large moles.
- Pregnant and/or breastfeeding.
- Having an infection, dermatitis or a rash in the treatment area.
- Significant concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.
- Suffering from coagulation disorders or taking prescription anticoagulation medications.
- History of keloid scarring, hypertrophic scarring or of abnormal wound healing.
- History of immunosuppression/immune deficiency disorders or currently using immunosuppressive medications.
- History of vitiligo, eczema, or psoriasis.
- History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.
- History of seizure disorders due to light.
- Any use of medication that is known to increase sensitivity to light according to Investigator's discretion.
- +9 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Scitonlead
Study Sites (1)
Refined Dermatology
Los Gatos, California, 95032, United States
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 29, 2019
First Posted
May 31, 2019
Study Start
April 12, 2019
Primary Completion
August 30, 2020
Study Completion
September 29, 2020
Last Updated
October 20, 2020
Record last verified: 2020-10